Patents are legal documents drawn up by inventors and lawyers and granted by various patent offices around the world, to protect the inventors' intellectual property. The short description accompanying each patent in this Patents section is therefore taken from the legal document as is, with minor corrections for Greek symbols and obvious spelling errors. The patents included in this section may be for material products (defensins or defensin-like peptides or nucleic acid sequences, synthetic or natural) or for novel methods of detecting, quantitating, synthesizing, or delivering antimicrobial peptides/nucleic acid sequences in general. The curators' criterion for inclusion in this section is broader for novel methods than for material products, in the hope that these methods may in future be similarly applied to defensins.

Patents in which the defensins or defensin-like material products and methods as above are not novel, such as biomarker sets containing unmodified defensin or defensin-like peptides or oligonucleotides, are excluded from this section. The exception to such exclusions is where the patent provides other novel defensin-related material products or methods in addition to those non-novel of the biomarker set itself. This exclusion is because the reasonable presence of defensin or defensin-like sequences or indeed any other sequences in patented biomarker sets is necessarily attributed to some prior discovery of disease state correlation with such sequences. The curators have observed therefore that the novel discovery in biomarker-related patents is often the method of biomarker array analysis and validation as well as its resultant implications for diagnostics and prognostics. The expert evaluation of such biomarker analysis and validation is well outside the scope of the Defensins Knowledgebase. The reader is respectfully referred to a biomarker database specific to the disease to perform his own assessment of the validity of the biomarker.

Methods not pertaining to the antimicrobial activity of defensins, but where defensins or antimicrobial peptides or small cationic peptides or disulphide-bonded peptides or their respective nucleic acid sequences are suggested in some unambiguous detail to play a useful role in the method, with or without supporting experimental evidence, are included as well in this section. Patents in which natural defensins are up/downregulated in a clearly defined signal transduction pathway as a result of the unrelated patented novel compound or method are also included. And lastly, all patents showing experimental work done with defensins or antimicrobial peptides or small cationic peptides or disulphide-bonded peptides or their respective nucleic acid sequences, where such peptides or nucleic acid sequences are not the experimental controls, are included without exception.

The data in this section have been extracted from the academic version of SciFinder Scholar 2007 and from public Google search - a wide range of defensin-related patents are included.


Results 81 - 90 of 333

<< Previous | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | Next >>

Last updated: 20th February 2008

Patent No.: US 271645
Intratracheal administration of lysozyme with other therapeutic agents in the prevention and treatment of respiratory disorders.
Applicant: Shteyngart B (2005)
The subject invention is directed to the prevention and treatment of respiratory disorders by intratracheal administration of an effective amt. of lysozyme, either alone or in combination with other therapeutic agents such as beta-defensins. Applicable respiratory disorders include, but are not limited to, pulmonary emphysema, asthma, bronchitis, pneumonia, respiratory distress syndrome, bronchopulmonary dysplasia, interstitial fibrosis, cystic fibrosis, and neoplasia. The method is intended for a variety of mammals, including humans ranging from premature neonates to adults.

Patent No.: US 257285
Fusion proteins of antimicrobial peptides for the prevention and treatment of plant disease caused by Xylella fastidiosa.
Applicant: Gupta G (2005)
Fusion proteins of anti-microbial peptides that can be used for the treatment and prophylaxis of plant diseases caused by the bacterial pathogen Xylella fastidiosa are provided. The anti-microbial proteins of the invention generally comprise a surface recognition domain capable of binding to a bacterial membrane component, fused to a bacterial lysis domain polypeptide, capable of affecting lysis or rupture of the bacterial membrane, typically via a fused polypeptide linker. The surface recognition domain may come from any protein that recognizes and targets a cell surface protein and so can bring the antimicrobial peptide into contact with the cell membrane. In particular, methods and compns. for the treatment or prevention of Pierce's disease of grapevines are provided. Methods for the generation of transgenic Vitus vinifera plants secreting these proteins into the xylem are also described. A mixt. of cecropin B (5 mM) and human neutrophil elastase (2.5 nM) was synergistic in killing of X. fastidiosa.

Patent No.: US 239889
In vivo release of endogenous anti-microbial mediators by leukotriene B4 (LTB4) administration.
Applicant: Gosselin J, Flamand L, Borgeat P (2005)
The invention relates to the in vivo release of endogenous anti-microbial mediators, such as alpha-defensin or MIP-1beta, by administering leukotriene B4, leukotriene B4 analogs, precursors, metabolites, or related compds. The present invention furthermore relates to the use of leukotriene B4 and related compds. for the treatment and/or prophylaxis of diseases that are pos. influenced by such anti-microbial mediators.

Patent No.: US 075292
Use of human beta defensin or its inducing agents for treating HIV-1 associated with chemokine receptor CXCR4.
Applicant: Weinberg A (2005)
The invention provides the protein, DNA and cDNA sequences of human beta-defensin 2 (HBD-2) and beta-defensin 3 (HBD-3) for the treatment and prevention of viral infections, and particularly HIV infections. The invention also provides the protein and DNA sequences of beta defensin inducing agent, protein FAD-I, from Fusobacterium nucleatum and human for treating AIDS. HIV-1 induces HBD-2 and HBD-3 but not HBD-1 mRNA in NHOEC. HBD-2 and HBD-3 inhibit HIV-1 replication and downmodulate chemokine receptor CXCR4.

Patent No.: US 0277176
Human and mouse beta-defensins, antimicrobial peptides.
Applicant: McCray PB, Schutte BC, Hong PJ, Casavant TL, Welsh M (2005)
The present invention employs an iterative application of BLAST and Hidden Markov Model (HMM) based searches which identified 34 beta-defensin genes in the human genome and 48 in the mouse genome. The present invention relates to novel antimicrobial peptides and derivatives thereof as well as the beta-defensin genes encoding the peptides. The invention further relates to methods of use of the peptides including a method of inhibiting microbial growth by administering an effective amount of the peptide alone or in combination with other antimicrobial agents or antibiotics.

Patent No.: US 0196480
Skin treatment method with lactobacillus extract.
Applicant: Sullivan M, Schnittger SF, Mammone T, Goyarts EC (2005)
The present invention relates to a method of stimulating beta-defensins in skin cells which comprises applying to the skin cells an effective amount of a Lactobacillus extract or active fraction thereof.

Patent No.: FR 2863893
Use of agents stimulating human beta-defensins type 2 and/or type 3, screening method, and therapeutic and cosmetic use.
Applicant: Perrier E, Guezennec A, Pernet I, Reymermier C, Guesnet J (2005)
The invention discloses agents able to stimulate, direct or indirect, the expression of human beta-defensins type 2 and/or type 3, characterized in that the agent does not involve inflammatory reactions, irritation or intolerance. The invention also provides a screening method, making it possible to select such agents. The invention finds application in prepn. of cosmetic or pharmaceutical compns. contg. such agents.

Patent No.: WO 4099368
Methods for detecting intracellular defensins in various leukocyte subpopulations.
Applicant: D'Costa SS (2004)
The present invention relates to methods and kits for detecting intracellular defensin expression in specific leukocyte subpopulations by flow cytometry. Specific leukocyte subpopulations may be identified by measuring the signals generated from one or more cell-distinguishing antibodies bound to cells in a sample. Intracellular defensin expression in specific leukocyte subpopulations may be detd. by measuring the signals generated from one or more defensin-specific antibodies bound to defensin inside the cells. These methods may be used to generate an intracellular defensin expression profile which may be useful for diagnosing and treating diseases and illnesses.

Patent No.: WO 110143
Retroviral expression constructs for fusion proteins of bactericidal proteins and targeting monoclonal antibodies for control of infection.
Applicant: Imboden M, Homan J, Bremel RD (2004)
Methods of targeting microbicidal proteins using fusion proteins with monoclonal antibodies to antigens of the microorganism are described. Retroviral expression vectors are used to manuf. the fusion protein in an animal cell expression host. These proteins can be used in the treatment of human or animal disease and in the prevention of disease, e.g. in treating plant and animal products in food processing. The present invention also relates to methods of using a fusion protein comprising a microorganism targeting mol. and a biocide in various diagnostic applications in no. of diverse fields such as agriculture, medicine, and national defense.

Patent No.: WO 106941
Methods for the detection of cardiovascular disorder plasma polypeptides (CPPs), their diagnostic uses, and screening for modulators thereof.
Applicant: Bougueleret L (2004)
The invention discloses human secreted polypeptides that circulate at an increased level in the plasma of patients with cardiovascular disorders. The invention also provides methods of using compns. including the polypeptides, polynucleotides encoding them, and antibodies specific for these polypeptides, for diagnosis, prognosis, and for drug development.